Search Results - "Tupinon, I."

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Prevention of early postmenopausal bone loss with cyclical etidronate therapy (A double-blind, placebo-controlled study and 1-year follow-up)

    Prevention of early postmenopausal bone loss with cyclical etidronate therapy (A double-blind, placebo-controlled study and 1-year follow-up) by MEUNIER, P. J, CONFAVREUX, E, TUPINON, I, HARDOUIN, C, DELMAS, P. D, BALENA, R

    “…The objective of the study was to evaluate the effects of cyclical therapy with etidronate and calcium on spinal and femoral bone loss in the early post…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism

    S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism by Sansilvestri-Morel, P, Bertin, F, Lapret, I, Neau, B, Blanc-Guillemaud, V, Petit-Dop, F, Tupinon-Mathieu, I, Delerive, P

    Published in European heart journal (01-11-2020)
    “…Abstract   Pulmonary embolism (PE) is the third leading cause of cardiovascular death in western countries. The enhancement of fibrinolysis constitutes a…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up)

    Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up) by Meunier, P. J., Confavreux, E., Tupinon, I., Hardouin, C., Delmas, P. D., Balena, R.

    “…Abstract The objective of the study was to evaluate the effects of cyclical therapy with etidronate and calcium on spinal and femoral bone loss in the early…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up)1

    Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up)1 by Meunier, P. J, Confavreux, E, Tupinon, I, Hardouin, C, Delmas, P. D, Balena, R

    “…The objective of the study was to evaluate the effects of cyclical therapy with etidronate and calcium on spinal and femoral bone loss in the early post…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    DXA parameters related to internal reference system as predictors of an in vivo variability of BMD measurement from a study on 3808 patients involving 75 centres

    DXA parameters related to internal reference system as predictors of an in vivo variability of BMD measurement from a study on 3808 patients involving 75 centres by Slosman, DO, Milsztain, N, Perron, C, Meunier, P, Reginster, Jean-Yves, Tupinon, I

    Published 1998
    Get full text
    Web Resource
    Save to List
    Saved in:
  6. 6
    Centralized quality management of bone densitometry for clinical trial and private practice: The use of ISO standard by GECAP (Geneva Quality Assessment Program)

    Centralized quality management of bone densitometry for clinical trial and private practice: The use of ISO standard by GECAP (Geneva Quality Assessment Program) by Slosman, DO, Milsztajn, NT, Billet, J, Reginster, Jean-Yves, Provvedini, D, Tupinon, I, Meunier, PJ

    Published 1998
    Get full text
    Web Resource
    Save to List
    Saved in:
  7. 7
    Safety of strontium ranelate in prevention of postmenopausal bone loss - a double-blind, prospective, placebo-controlled study

    Safety of strontium ranelate in prevention of postmenopausal bone loss - a double-blind, prospective, placebo-controlled study by Reginster, Jean-Yves, Roux, C, Jupsin, I, Tupinon-Mathieu, I, Tsouderos, Y

    Published 1999
    Get full text
    Web Resource
    Save to List
    Saved in:

Search Tools: